Initiation of Antiretroviral Therapy During Acute HIV-1 Infection Leads to a High Rate of Nonreactive HIV Serology.
Mark S de Souza, Suteeraporn Pinyakorn, Siriwat Akapirat...
https://pubmed.ncbi.nlm.nih.gov/27317797/Actively Recruiting
Led by SEARCH Research Foundation · Updated on 2025-06-04
900
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating antiretroviral therapy ART for people with acute and chronic HIV infection. This study compares outcomes in different body tissues, including genital secretions, central nervous system, gut, and lymph nodes, among individuals starting treatment during acute versus chronic HIV infection. The study includes participants from two related HIV studies in Thai populations, focusing on immune and virologic responses at various infection stages and ART regimens. Participants receive a highly active antiretroviral therapy HAART regimen consisting of one or two nucleosidenucleotide reverse-transcriptase inhibitors plus dolutegravir DTG 50 mg taken orally once daily. The treatment aims to evaluate HIV control and immune function over time. The study follows participants long-term to assess clinical, immunologic, and virologic outcomes, comparing those who start treatment early with those treated during chronic infection. During the study, participants undergo regular monitoring of HIV-related clinical events, immune cell counts, viral load, and drug resistance. Assessments also include functional brain imaging, neuropsychological testing, and analysis of immune activation markers in blood and tissue samples. Researchers track adherence to ART and adverse events related to treatment. The total follow-up period extends over 10 years, allowing comprehensive evaluation of treatment effects and disease progression.
CONDITIONS
Antiretroviral Therapy for Acute and Chronic HIV Infection
N
Nitiya Chomchey, RN, PhD
T
Tassanee Luekasemsuk, MSc
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
SEARCH Research Foundation
Lead Sponsor
ViiV Healthcare
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 10 years
Participants receive antiretroviral therapy consisting of 1 or 2 nucleoside/nucleotide analog reverse-transcriptase inhibitor medications plus dolutegravir 50 mg orally once daily.
Regular follow-up visits to monitor treatment adherence, HIV-related clinical events, and immune and virologic parameters
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Mark S de Souza, Suteeraporn Pinyakorn, Siriwat Akapirat...
https://pubmed.ncbi.nlm.nih.gov/27317797/Jintanat Ananworanich, Leigh Anne Eller, Suteeraporn Pinyakorn...
https://pubmed.ncbi.nlm.nih.gov/28691436/SEARCH Research Foundation
Lead Sponsor
ViiV Healthcare
Collaborating Sponsor